Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

BACKGROUND: This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently responding to previous anti-spasticity medications. METHODS: Of 2...

詳細記述

保存先:
書誌詳細
出版年:BMC Neurol
主要な著者: D’hooghe, Marie, Willekens, Barbara, Delvaux, Valerie, D’haeseleer, Miguel, Guillaume, Daniel, Laureys, Guy, Nagels, Guy, Vanderdonckt, Patrick, Van Pesch, Vincent, Popescu, Veronica
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2021
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8218396/
https://ncbi.nlm.nih.gov/pubmed/34157999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-021-02246-0
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料